The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Neurodegenerative Diseases Therapeutics Market Research Report 2024
Synopsis
Market Analysis and Insights: Global Neurodegenerative Diseases Therapeutics Market
The global Neurodegenerative Diseases Therapeutics market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Multiple Sclerosis Therapeutics accounting for % of the Neurodegenerative Diseases Therapeutics global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Child segment is altered to an % CAGR throughout this forecast period.
China Neurodegenerative Diseases Therapeutics market size is valued at US$ million in 2021, while the North America and Europe Neurodegenerative Diseases Therapeutics are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Neurodegenerative Diseases Therapeutics landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Neurodegenerative Diseases Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Neurodegenerative Diseases Therapeutics market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Neurodegenerative Diseases Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Neurodegenerative Diseases Therapeutics market.
Global Neurodegenerative Diseases Therapeutics Scope and Market Size
Neurodegenerative Diseases Therapeutics market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Neurodegenerative Diseases Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Multiple Sclerosis Therapeutics
Alzheimer's Disease Therapeutics
Parkinson's Disease Therapeutics
Parkinson's Disease Therapeutics
Others
Segment by Application
Child
Aldult
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
AB Science SA
AbbVie Inc.
Acadia Pharmaceuticals Inc.
Biogen Inc.
F. Hoffmann La Roche Ltd.
H Lundbeck AS
Mitsubishi Chemical Holdings Corp.
Novartis AG
Sanofi
Teva Pharmaceutical Industries Ltd
Market Analysis and Insights: Global Neurodegenerative Diseases Therapeutics Market
The global Neurodegenerative Diseases Therapeutics market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Multiple Sclerosis Therapeutics accounting for % of the Neurodegenerative Diseases Therapeutics global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Child segment is altered to an % CAGR throughout this forecast period.
China Neurodegenerative Diseases Therapeutics market size is valued at US$ million in 2021, while the North America and Europe Neurodegenerative Diseases Therapeutics are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Neurodegenerative Diseases Therapeutics landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Neurodegenerative Diseases Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Neurodegenerative Diseases Therapeutics market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Neurodegenerative Diseases Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Neurodegenerative Diseases Therapeutics market.
Global Neurodegenerative Diseases Therapeutics Scope and Market Size
Neurodegenerative Diseases Therapeutics market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Neurodegenerative Diseases Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Multiple Sclerosis Therapeutics
Alzheimer's Disease Therapeutics
Parkinson's Disease Therapeutics
Parkinson's Disease Therapeutics
Others
Segment by Application
Child
Aldult
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
AB Science SA
AbbVie Inc.
Acadia Pharmaceuticals Inc.
Biogen Inc.
F. Hoffmann La Roche Ltd.
H Lundbeck AS
Mitsubishi Chemical Holdings Corp.
Novartis AG
Sanofi
Teva Pharmaceutical Industries Ltd
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neurodegenerative Diseases Therapeutics Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Multiple Sclerosis Therapeutics
1.2.3 Alzheimer's Disease Therapeutics
1.2.4 Parkinson's Disease Therapeutics
1.2.5 Parkinson's Disease Therapeutics
1.2.6 Others
1.3 Market by Application
1.3.1 Global Neurodegenerative Diseases Therapeutics Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Child
1.3.3 Aldult
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Neurodegenerative Diseases Therapeutics Market Perspective (2017-2028)
2.2 Neurodegenerative Diseases Therapeutics Growth Trends by Region
2.2.1 Neurodegenerative Diseases Therapeutics Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Neurodegenerative Diseases Therapeutics Historic Market Size by Region (2017-2022)
2.2.3 Neurodegenerative Diseases Therapeutics Forecasted Market Size by Region (2023-2028)
2.3 Neurodegenerative Diseases Therapeutics Market Dynamics
2.3.1 Neurodegenerative Diseases Therapeutics Industry Trends
2.3.2 Neurodegenerative Diseases Therapeutics Market Drivers
2.3.3 Neurodegenerative Diseases Therapeutics Market Challenges
2.3.4 Neurodegenerative Diseases Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neurodegenerative Diseases Therapeutics Players by Revenue
3.1.1 Global Top Neurodegenerative Diseases Therapeutics Players by Revenue (2017-2022)
3.1.2 Global Neurodegenerative Diseases Therapeutics Revenue Market Share by Players (2017-2022)
3.2 Global Neurodegenerative Diseases Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Neurodegenerative Diseases Therapeutics Revenue
3.4 Global Neurodegenerative Diseases Therapeutics Market Concentration Ratio
3.4.1 Global Neurodegenerative Diseases Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neurodegenerative Diseases Therapeutics Revenue in 2021
3.5 Neurodegenerative Diseases Therapeutics Key Players Head office and Area Served
3.6 Key Players Neurodegenerative Diseases Therapeutics Product Solution and Service
3.7 Date of Enter into Neurodegenerative Diseases Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Neurodegenerative Diseases Therapeutics Breakdown Data by Type
4.1 Global Neurodegenerative Diseases Therapeutics Historic Market Size by Type (2017-2022)
4.2 Global Neurodegenerative Diseases Therapeutics Forecasted Market Size by Type (2023-2028)
5 Neurodegenerative Diseases Therapeutics Breakdown Data by Application
5.1 Global Neurodegenerative Diseases Therapeutics Historic Market Size by Application (2017-2022)
5.2 Global Neurodegenerative Diseases Therapeutics Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Neurodegenerative Diseases Therapeutics Market Size (2017-2028)
6.2 North America Neurodegenerative Diseases Therapeutics Market Size by Country (2017-2022)
6.3 North America Neurodegenerative Diseases Therapeutics Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Neurodegenerative Diseases Therapeutics Market Size (2017-2028)
7.2 Europe Neurodegenerative Diseases Therapeutics Market Size by Country (2017-2022)
7.3 Europe Neurodegenerative Diseases Therapeutics Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size (2017-2028)
8.2 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size by Country (2017-2022)
8.3 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Neurodegenerative Diseases Therapeutics Market Size (2017-2028)
9.2 Latin America Neurodegenerative Diseases Therapeutics Market Size by Country (2017-2022)
9.3 Latin America Neurodegenerative Diseases Therapeutics Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size (2017-2028)
10.2 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Country (2017-2022)
10.3 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 AB Science SA
11.1.1 AB Science SA Company Detail
11.1.2 AB Science SA Business Overview
11.1.3 AB Science SA Neurodegenerative Diseases Therapeutics Introduction
11.1.4 AB Science SA Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022)
11.1.5 AB Science SA Recent Development
11.2 AbbVie Inc.
11.2.1 AbbVie Inc. Company Detail
11.2.2 AbbVie Inc. Business Overview
11.2.3 AbbVie Inc. Neurodegenerative Diseases Therapeutics Introduction
11.2.4 AbbVie Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022)
11.2.5 AbbVie Inc. Recent Development
11.3 Acadia Pharmaceuticals Inc.
11.3.1 Acadia Pharmaceuticals Inc. Company Detail
11.3.2 Acadia Pharmaceuticals Inc. Business Overview
11.3.3 Acadia Pharmaceuticals Inc. Neurodegenerative Diseases Therapeutics Introduction
11.3.4 Acadia Pharmaceuticals Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022)
11.3.5 Acadia Pharmaceuticals Inc. Recent Development
11.4 Biogen Inc.
11.4.1 Biogen Inc. Company Detail
11.4.2 Biogen Inc. Business Overview
11.4.3 Biogen Inc. Neurodegenerative Diseases Therapeutics Introduction
11.4.4 Biogen Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022)
11.4.5 Biogen Inc. Recent Development
11.5 F. Hoffmann La Roche Ltd.
11.5.1 F. Hoffmann La Roche Ltd. Company Detail
11.5.2 F. Hoffmann La Roche Ltd. Business Overview
11.5.3 F. Hoffmann La Roche Ltd. Neurodegenerative Diseases Therapeutics Introduction
11.5.4 F. Hoffmann La Roche Ltd. Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022)
11.5.5 F. Hoffmann La Roche Ltd. Recent Development
11.6 H Lundbeck AS
11.6.1 H Lundbeck AS Company Detail
11.6.2 H Lundbeck AS Business Overview
11.6.3 H Lundbeck AS Neurodegenerative Diseases Therapeutics Introduction
11.6.4 H Lundbeck AS Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022)
11.6.5 H Lundbeck AS Recent Development
11.7 Mitsubishi Chemical Holdings Corp.
11.7.1 Mitsubishi Chemical Holdings Corp. Company Detail
11.7.2 Mitsubishi Chemical Holdings Corp. Business Overview
11.7.3 Mitsubishi Chemical Holdings Corp. Neurodegenerative Diseases Therapeutics Introduction
11.7.4 Mitsubishi Chemical Holdings Corp. Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022)
11.7.5 Mitsubishi Chemical Holdings Corp. Recent Development
11.8 Novartis AG
11.8.1 Novartis AG Company Detail
11.8.2 Novartis AG Business Overview
11.8.3 Novartis AG Neurodegenerative Diseases Therapeutics Introduction
11.8.4 Novartis AG Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022)
11.8.5 Novartis AG Recent Development
11.9 Sanofi
11.9.1 Sanofi Company Detail
11.9.2 Sanofi Business Overview
11.9.3 Sanofi Neurodegenerative Diseases Therapeutics Introduction
11.9.4 Sanofi Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022)
11.9.5 Sanofi Recent Development
11.10 Teva Pharmaceutical Industries Ltd
11.10.1 Teva Pharmaceutical Industries Ltd Company Detail
11.10.2 Teva Pharmaceutical Industries Ltd Business Overview
11.10.3 Teva Pharmaceutical Industries Ltd Neurodegenerative Diseases Therapeutics Introduction
11.10.4 Teva Pharmaceutical Industries Ltd Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022)
11.10.5 Teva Pharmaceutical Industries Ltd Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Neurodegenerative Diseases Therapeutics Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
Table 2. Key Players of Multiple Sclerosis Therapeutics
Table 3. Key Players of Alzheimer's Disease Therapeutics
Table 4. Key Players of Parkinson's Disease Therapeutics
Table 5. Key Players of Parkinson's Disease Therapeutics
Table 6. Key Players of Others
Table 7. Global Neurodegenerative Diseases Therapeutics Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
Table 8. Global Neurodegenerative Diseases Therapeutics Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 9. Global Neurodegenerative Diseases Therapeutics Market Size by Region (2017-2022) & (US$ Million)
Table 10. Global Neurodegenerative Diseases Therapeutics Market Share by Region (2017-2022)
Table 11. Global Neurodegenerative Diseases Therapeutics Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 12. Global Neurodegenerative Diseases Therapeutics Market Share by Region (2023-2028)
Table 13. Neurodegenerative Diseases Therapeutics Market Trends
Table 14. Neurodegenerative Diseases Therapeutics Market Drivers
Table 15. Neurodegenerative Diseases Therapeutics Market Challenges
Table 16. Neurodegenerative Diseases Therapeutics Market Restraints
Table 17. Global Neurodegenerative Diseases Therapeutics Revenue by Players (2017-2022) & (US$ Million)
Table 18. Global Neurodegenerative Diseases Therapeutics Market Share by Players (2017-2022)
Table 19. Global Top Neurodegenerative Diseases Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Diseases Therapeutics as of 2021)
Table 20. Ranking of Global Top Neurodegenerative Diseases Therapeutics Companies by Revenue (US$ Million) in 2021
Table 21. Global 5 Largest Players Market Share by Neurodegenerative Diseases Therapeutics Revenue (CR5 and HHI) & (2017-2022)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Neurodegenerative Diseases Therapeutics Product Solution and Service
Table 24. Date of Enter into Neurodegenerative Diseases Therapeutics Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Neurodegenerative Diseases Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 27. Global Neurodegenerative Diseases Therapeutics Revenue Market Share by Type (2017-2022)
Table 28. Global Neurodegenerative Diseases Therapeutics Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 29. Global Neurodegenerative Diseases Therapeutics Revenue Market Share by Type (2023-2028)
Table 30. Global Neurodegenerative Diseases Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 31. Global Neurodegenerative Diseases Therapeutics Revenue Market Share by Application (2017-2022)
Table 32. Global Neurodegenerative Diseases Therapeutics Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 33. Global Neurodegenerative Diseases Therapeutics Revenue Market Share by Application (2023-2028)
Table 34. North America Neurodegenerative Diseases Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 35. North America Neurodegenerative Diseases Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 36. Europe Neurodegenerative Diseases Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 37. Europe Neurodegenerative Diseases Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 38. Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size by Region (2017-2022) & (US$ Million)
Table 39. Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size by Region (2023-2028) & (US$ Million)
Table 40. Latin America Neurodegenerative Diseases Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 41. Latin America Neurodegenerative Diseases Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 42. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 43. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 44. AB Science SA Company Detail
Table 45. AB Science SA Business Overview
Table 46. AB Science SA Neurodegenerative Diseases Therapeutics Product
Table 47. AB Science SA Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022) & (US$ Million)
Table 48. AB Science SA Recent Development
Table 49. AbbVie Inc. Company Detail
Table 50. AbbVie Inc. Business Overview
Table 51. AbbVie Inc. Neurodegenerative Diseases Therapeutics Product
Table 52. AbbVie Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022) & (US$ Million)
Table 53. AbbVie Inc. Recent Development
Table 54. Acadia Pharmaceuticals Inc. Company Detail
Table 55. Acadia Pharmaceuticals Inc. Business Overview
Table 56. Acadia Pharmaceuticals Inc. Neurodegenerative Diseases Therapeutics Product
Table 57. Acadia Pharmaceuticals Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022) & (US$ Million)
Table 58. Acadia Pharmaceuticals Inc. Recent Development
Table 59. Biogen Inc. Company Detail
Table 60. Biogen Inc. Business Overview
Table 61. Biogen Inc. Neurodegenerative Diseases Therapeutics Product
Table 62. Biogen Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022) & (US$ Million)
Table 63. Biogen Inc. Recent Development
Table 64. F. Hoffmann La Roche Ltd. Company Detail
Table 65. F. Hoffmann La Roche Ltd. Business Overview
Table 66. F. Hoffmann La Roche Ltd. Neurodegenerative Diseases Therapeutics Product
Table 67. F. Hoffmann La Roche Ltd. Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022) & (US$ Million)
Table 68. F. Hoffmann La Roche Ltd. Recent Development
Table 69. H Lundbeck AS Company Detail
Table 70. H Lundbeck AS Business Overview
Table 71. H Lundbeck AS Neurodegenerative Diseases Therapeutics Product
Table 72. H Lundbeck AS Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022) & (US$ Million)
Table 73. H Lundbeck AS Recent Development
Table 74. Mitsubishi Chemical Holdings Corp. Company Detail
Table 75. Mitsubishi Chemical Holdings Corp. Business Overview
Table 76. Mitsubishi Chemical Holdings Corp. Neurodegenerative Diseases Therapeutics Product
Table 77. Mitsubishi Chemical Holdings Corp. Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022) & (US$ Million)
Table 78. Mitsubishi Chemical Holdings Corp. Recent Development
Table 79. Novartis AG Company Detail
Table 80. Novartis AG Business Overview
Table 81. Novartis AG Neurodegenerative Diseases Therapeutics Product
Table 82. Novartis AG Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022) & (US$ Million)
Table 83. Novartis AG Recent Development
Table 84. Sanofi Company Detail
Table 85. Sanofi Business Overview
Table 86. Sanofi Neurodegenerative Diseases Therapeutics Product
Table 87. Sanofi Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022) & (US$ Million)
Table 88. Sanofi Recent Development
Table 89. Teva Pharmaceutical Industries Ltd Company Detail
Table 90. Teva Pharmaceutical Industries Ltd Business Overview
Table 91. Teva Pharmaceutical Industries Ltd Neurodegenerative Diseases Therapeutics Product
Table 92. Teva Pharmaceutical Industries Ltd Revenue in Neurodegenerative Diseases Therapeutics Business (2017-2022) & (US$ Million)
Table 93. Teva Pharmaceutical Industries Ltd Recent Development
Table 94. Research Programs/Design for This Report
Table 95. Key Data Information from Secondary Sources
Table 96. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neurodegenerative Diseases Therapeutics Market Share by Type: 2021 VS 2028
Figure 2. Multiple Sclerosis Therapeutics Features
Figure 3. Alzheimer's Disease Therapeutics Features
Figure 4. Parkinson's Disease Therapeutics Features
Figure 5. Parkinson's Disease Therapeutics Features
Figure 6. Others Features
Figure 7. Global Neurodegenerative Diseases Therapeutics Market Share by Application in 2021 & 2028
Figure 8. Child Case Studies
Figure 9. Aldult Case Studies
Figure 10. Neurodegenerative Diseases Therapeutics Report Years Considered
Figure 11. Global Neurodegenerative Diseases Therapeutics Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 12. Global Neurodegenerative Diseases Therapeutics Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 13. Global Neurodegenerative Diseases Therapeutics Market Share by Region: 2021 VS 2028
Figure 14. Global Neurodegenerative Diseases Therapeutics Market Share by Players in 2021
Figure 15. Global Top Neurodegenerative Diseases Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Diseases Therapeutics as of 2021)
Figure 16. The Top 10 and 5 Players Market Share by Neurodegenerative Diseases Therapeutics Revenue in 2021
Figure 17. North America Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 18. North America Neurodegenerative Diseases Therapeutics Market Share by Country (2017-2028)
Figure 19. United States Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 20. Canada Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 21. Europe Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 22. Europe Neurodegenerative Diseases Therapeutics Market Share by Country (2017-2028)
Figure 23. Germany Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 24. France Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 25. U.K. Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 26. Italy Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. Russia Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. Nordic Countries Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Asia-Pacific Neurodegenerative Diseases Therapeutics Market Share by Region (2017-2028)
Figure 31. China Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Japan Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. South Korea Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. Southeast Asia Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 35. India Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. Australia Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. Latin America Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. Latin America Neurodegenerative Diseases Therapeutics Market Share by Country (2017-2028)
Figure 39. Mexico Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Brazil Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Share by Country (2017-2028)
Figure 43. Turkey Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 44. Saudi Arabia Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 45. AB Science SA Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2017-2022)
Figure 46. AbbVie Inc. Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2017-2022)
Figure 47. Acadia Pharmaceuticals Inc. Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2017-2022)
Figure 48. Biogen Inc. Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2017-2022)
Figure 49. F. Hoffmann La Roche Ltd. Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2017-2022)
Figure 50. H Lundbeck AS Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2017-2022)
Figure 51. Mitsubishi Chemical Holdings Corp. Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2017-2022)
Figure 52. Novartis AG Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2017-2022)
Figure 53. Sanofi Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2017-2022)
Figure 54. Teva Pharmaceutical Industries Ltd Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2017-2022)
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Figure 57. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
